Literature DB >> 2968907

Poor efficacy of teicoplanin in treatment of deep-seated staphylococcal infections.

N Galanakis1, H Giamarellou, N Vlachogiannis, C Dendrinos, G K Daikos.   

Abstract

Teicoplanin in a 400 mg intravenous loading dose followed by 200 mg/day intravenously or intramuscularly was given to 19 patients with deep-seated staphylococcal infections. Only eight patients (44.4%) were considered cured, failure mostly being observed in patients with osteomyelitis, endocarditis and bacteremia. Poor tissue kinetics of teicoplanin and the presence of foreign bodies are probable explanations for the reported failures. Future trials using a higher dose of teicoplanin with or without the addition of rifampicin or gentamicin seem to be justified.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2968907     DOI: 10.1007/bf01963065

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  11 in total

1.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

2.  Teicoplanin.

Authors:  A H Williams; R N Grüneberg
Journal:  J Antimicrob Chemother       Date:  1984-11       Impact factor: 5.790

3.  'Methicillin resistant' Staphylococcus aureus infections during 1978-79: clinical and bacteriologic observations.

Authors:  H Giamarellou; M Papapetropoulou; G K Daikos
Journal:  J Antimicrob Chemother       Date:  1981-06       Impact factor: 5.790

4.  Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests.

Authors:  L B Reller; C W Stratton
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

5.  In vitro activity and human pharmacokinetics of teicoplanin.

Authors:  L Verbist; B Tjandramaga; B Hendrickx; A Van Hecken; P Van Melle; R Verbesselt; J Verhaegen; P J De Schepper
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

Review 6.  Staphylococcal endocarditis. Laboratory and clinical basis for antibiotic therapy.

Authors:  A W Karchmer
Journal:  Am J Med       Date:  1985-06-28       Impact factor: 4.965

7.  In vitro activity of teichomycin compared with those of other antibiotics.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

8.  Teichomycin: in-vitro and in-vivo evaluation in comparison with other antibiotics.

Authors:  R Pallanza; M Berti; B P Goldstein; E Mapelli; E Randisi; R Scotti; V Arioli
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

9.  Therapeutic efficacy of teicoplanin in experimental enterococcal endocarditis.

Authors:  P M Sullam; M G Täuber; C J Hackbarth; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1985-01       Impact factor: 5.191

10.  Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections.

Authors:  P Calain; K H Krause; P Vaudaux; R Auckenthaler; D Lew; F Waldvogel; B Hirschel
Journal:  J Infect Dis       Date:  1987-02       Impact factor: 5.226

View more
  13 in total

1.  Protein binding of vancomycin in a patient with immunoglobulin A myeloma.

Authors:  T G Cantú; J D Dick; D E Elliott; R L Humphrey; D M Kornhauser
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

2.  Clinical efficacy of teicoplanin.

Authors:  P Calain; F Waldvogel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-02       Impact factor: 3.267

3.  Treatment failure with teicoplanin and response to oral antibiotic regimens.

Authors:  P H McWhinney
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

Review 4.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

Review 5.  Future prospects and therapeutic potential of streptogramins.

Authors:  E Rubinstein; N Keller
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 6.  Anti-gram-positive agents. What we have and what we would like.

Authors:  R N Grüneberg
Journal:  Drugs       Date:  1997       Impact factor: 9.546

7.  Usefulness of teicoplanin for preventing methicillin-resistant Staphylococcus aureus infections in orthopedic surgery.

Authors:  A Soriano; D Popescu; S García; G Bori; J A Martínez; V Balasso; F Marco; M Almela; J Mensa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-01       Impact factor: 3.267

8.  Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program.

Authors:  F Menichetti; P Martino; G Bucaneve; G Gentile; D D'Antonio; V Liso; P Ricci; A M Nosari; M Buelli; M Carotenuto
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

9.  Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon.

Authors:  D N Gilbert; C A Wood; R C Kimbrough
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

10.  Beta-lactams versus glycopeptides in treatment of subcutaneous abscesses infected with Staphylococcus aureus.

Authors:  C A Wood; R M Wisniewski
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.